Friday, 16 October 2026European Markets

CASINO GUICHARD Stock Bullish Momentum With A 11.32% Jump Before The Weekend

Loading stream...

(vianews) - the market ended the session with casino guichard (co.pa) rising 11.32% to €3.88 on friday, after two successive sessions in a row of gains. cac 40 rose 0.65% to €7,432.77, after three successive sessions in a row of gains, on what was a somewhat positive trend trading session today.

casino guichard's last close was €3.48, 75.41% under its 52-week high of €14.16.

about casino guichard

casino, guichard-perrachon s.a. operates as a food retailer in france, latin america, and internationally. the company operates hypermarkets, supermarkets, shopping malls, and e-commerce sites, as well as convenience, discount, and cash and carry stores. it also involved in banking, digital marketing, service station, franchise, real estate asset management, property development and trading, rental, banking, and energy-related activities. it operates through stores. the company was founded in 1898 and is based in saint-étienne, france.

earnings per share

as for profitability, casino guichard has a trailing twelve months eps of €-3.34.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -5.53%.

revenue growth

year-on-year quarterly revenue growth grew by 9.3%, now sitting on 34b for the twelve trailing months.

sales growth

casino guichard's sales growth for the next quarter is negative 11.2%.

yearly top and bottom value

casino guichard's stock is valued at €3.88 at 22:30 est, way below its 52-week high of €14.16 and way above its 52-week low of €2.64.

volume

today's last reported volume for casino guichard is 1158460 which is 0.98% below its average volume of 1170040.

more news about casino guichard (co.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com